(redirected from Lisdexamfetamine)
Also found in: Dictionary, Medical, Wikipedia.
Related to Lisdexamfetamine: lisdexamfetamine dimesylate
LDXLoad X (6502 processor instruction)
LDXLong Distance Extender
LDXLong-Distance Xerox
LDXLogo Design Experts (est. 2000)
LDXLow Density Line
LDXLisdexamfetamine (aka Lisdexamfetamine Dimesylate; stimulant)
LDXLisdexamfetamine Dimesylate (aka Lisdexamfetamine; stimulant)
References in periodicals archive ?
The lisdexamfetamine was discontinued, and he was cautioned not to start it again.
Lisdexamfetamine dimesylate, a class II stimulant, was approved in 2012 by the Food and Drug Administration for adult ADHD.
Drug interactions: Lisdexamfetamine may alter the therapeutic effects of adrenergic blockers, tricyclic antidepressants, antihistamines, antihypertensives, ethosuximide, meperidine, norepinephrine, phenobarbital, phenytoin, and Veratrum alkaloids.
Patients were assigned to placebo or to lisdexamfetamine at 30, 50, or 70 mg/day.
Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
Lisdexamfetamine Dimesylate In Children And Adolescents With Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo- And Active Controlled, Dose-Optimized Study In Europe.
2, 2015 /PRNewswire-USNewswire/ -- The United States Food and Drug Administration (FDA) recently approved lisdexamfetamine dimesylate, under the brand name Vyvanse, to treat moderate to severe binge eating disorder (BED) in adults, a first of its kind prescription drug specifically indicated for BED.
The Court's summary judgment ruling concerning Shire's motion included 18 patent claims from four of the FDA Orange Book-listed patents for Vyvanse, which cover Vyvanse's active ingredient, the lisdexamfetamine dimesylate compound, and a method of using lisdexamfetamine dimesylate for the treatment of ADHD.
Long-acting preparations--extended-release and transdermal formulations and the prodrug lisdexamfetamine (Vyvanse)--have minimal potential to be misused and are preferable to immediate-release forms, Dr.
Watson"), advising of the filing of Abbreviated New Drug Applications ("ANDA") by each company for generic version of all strengths of lisdexamfetamine dimesylate capsules, VYVANSE.
SAN DIEGO -- Lisdexamfetamine, the recently approved once-daily medication for attention-deficit/hyperactivity disorder that appears to have low abuse potential, was safe and effective when given for a full year, and guanfacine, an investigational alpha-2A-adrenoreceptor, produced substantial improvement in a phase III trial, according to studies presented at the annual meeting of the American Psychiatric Association.
In addition, lisdexamfetamine dimesylate is currently available in eight European countries indicated as part of a comprehensive treatment programme for ADHD in children and adolescents 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate (brand names Elvanse[sup.